News

Filter

Current filters:

Gastro-intestinalsUCB

Impax Labs confirms patent challenge to Pfizer/UCB's Toviaz

04-07-2013

US specialty drugmaker Impax Laboratories (Nasdaq: IPXL) yesterday confirmed that it has initiated a…

Gastro-intestinalsGenericsImpax LaboratoriesNorth AmericaPatentsPfizerToviazUCB

US gastroenterologists increasingly using biologics to treat Crohn's patients in remission

06-03-2013

Although there have been no significant changes with regard to biologic treatment and Crohn's disease…

AbbVieBiotechnologyCimziaGastro-intestinalsHumiraJanssenMarkets & MarketingNorth AmericaPharmaceuticalRemicadeUCB

Back to top